1. Home
  2. URGN vs UAN Comparison

URGN vs UAN Comparison

Compare URGN & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$18.73

Market Cap

922.1M

Sector

Health Care

ML Signal

N/A

Logo CVR Partners LP

UAN

CVR Partners LP

N/A

Current Price

$138.50

Market Cap

1.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
URGN
UAN
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
1.1B
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
URGN
UAN
Price
$18.73
$138.50
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$29.29
N/A
AVG Volume (30 Days)
816.7K
87.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.58%
EPS Growth
N/A
61.98
EPS
N/A
9.33
Revenue
$1,128,000.00
$606,038,000.00
Revenue This Year
$119.37
N/A
Revenue Next Year
$64.79
N/A
P/E Ratio
N/A
$14.90
Revenue Growth
N/A
15.36
52 Week Low
$3.42
$63.45
52 Week High
$30.00
$139.50

Technical Indicators

Market Signals
Indicator
URGN
UAN
Relative Strength Index (RSI) 40.60 71.35
Support Level $18.55 $96.72
Resistance Level $20.44 N/A
Average True Range (ATR) 1.46 6.17
MACD -0.17 3.08
Stochastic Oscillator 17.91 96.53

Price Performance

Historical Comparison
URGN
UAN

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

Share on Social Networks: